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Decision aids in North American breast cancer outpatients have been shown to assist with treatment decision making and reduce
decisional conflict. To date, appropriate delivery formats to effectively increase patient participation in newly diagnosed breast cancer
inpatients have not been investigated in the context of German health care provision. The impact of a decision aid intervention was
studied in patients (n¼111) with a strong suspicion of breast cancer in a randomised controlled trial. The primary outcome variable
was decisional conflict. Participants were followed up 1 week post-intervention with a retention rate of 92%. Analyses revealed that
the intervention group felt better informed (Zp
2¼0.06) but did not experience an overall reduction in decisional conflict as compared
with the control group. The intervention had no effect on uptake rates of treatment options, length of consultation with the surgeon,
time point of treatment decision making, perceived involvement in decision making, neither decision related nor general patient
satisfaction. Patients who received the decision aid intervention experienced a small benefit with regards to how informed they felt
about advantages and disadvantages of relevant treatment options. Results are discussed in terms of contextual factors and individual
differences as moderators of treatment decision aid effectiveness.
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Patient involvement in treatment decision making has been
increasingly advocated in oncology. Many patients with breast
cancer, however, do not feel adequately involved in treatment
decision making (Bruera et al, 2002; Keating et al, 2002; Janz et al,
2004) and experience communication barriers with physicians
(Sepucha et al, 2002).
Although most intervention studies on shared decision making
have been completed in Canada and the United States, the impact
of this approach in European health care systems remains unclear.
Existing patriarchal physician attitudes and a more hierarchical
health care system in Germany may make it more difficult to
implement shared decision making into oncology health care
provision. These specifics within the health care system may have
created a culture of doctor–patient interaction that can complicate
the implementation of shared decision making. In addition, the
treatment of cancer patients is routinely offered in an inpatient
setting in specialised centres or programs which may influence the
efficacy of interventions, most likely in an impeding way, as
inpatient care usually results in more passive patient behaviour,
which in turn is less likely to be compatible with a shared decision
making approach.
Despite these hypothesised hindrances and with the aim to
develop new models of care, the German Ministry of Health
announced a focus programme in 2001 to start research in the area
of shared medical decision making. The current study reports on a
model project of breast cancer treatment within this framework.
Given the importance of surgical and chemotherapy treatment
for patients’ quality of life (Moyer, 1997; Mols et al, 2005; Nelson
et al, 2007) and that some treatment alternatives exist, sensitive
decision making accounting for the patients’ preferences should be
the ultimate goal for routine care. To achieve this aim, decision
aids have been developed as a tool to facilitate patient involvement
in treatment decision making. Decision aids provide patients with
disease-specific knowledge and assist in the recognition and the
appreciation of their personal values to achieve informed
decisions. Across diseases, decision aid interventions have
demonstrated effects on patient knowledge, decisional conflict,
concordance rates between values and the option chosen, and on
patients’ active role in decisions (O’Connor et al, 2003).
Although not all studies showed benefits (Goel et al, 2001),
intervention studies in patients with newly diagnosed breast cancer
found that decision aids increase patient knowledge (Sawka et al,
1998; Whelan et al, 2003, 2004) and affect surgical (Street et al,
1995; Molenaar et al, 2001; Katz et al, 2005; Lantz et al, 2005) as
well as adjuvant treatment decision making (Peele et al, 2005;
Siminoff et al, 2006).
Although several studies explored the effect of decision aid
interventions on treatment decision making as a proxy for the
effectiveness of the intervention, we believe that patient attitudes
toward the decision making process may be a more important
indicator of shared decision making effectiveness as the ultimate
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streatment choice may depend on several individual factors. Of
these, decisional conflict has been demonstrated to be a sensitive
measure of decision aid effectiveness (O’Connor et al, 2003).
To date, all randomised controlled trials in women with breast
cancer have been conducted in North America. Therefore, the aim
of this study was to examine the impact of a decision aid
intervention in breast cancer inpatients in Germany. Because of
the predominance of the inpatient treatment setting, we posited
that decision aid interventions may have different, and presumably
fewer effects due to the shorter time frame for decision making and
the loss of a certain degree of patient autonomy from hospital
admission. Therefore, we wanted to test whether or not effects on
decisional conflict and higher patient information status could be
replicated in this context. Consequently, experienced decisional
conflict was considered the primary outcome variable.
We were also interested in whether or not the intervention may
have changed the doctor—patient encounter with greater patient
activation by the physician, more information seeking by the patient,
or whether or not the intervention lead to more time needed for the
consultation. It was expected that the intervention would encourage
a more active patient role including more questioning behaviour or
alternatively, the intervention may have clarified questions that the
senior physician may have otherwise been asked, therefore, reducing
patient participation in the consultation.
We further expected that the decision aid intervention might delay
treatment decision making, with more patient involvement resulting
in longer periods of time to consider potential treatment options.
Although essentially null effects were reported in a meta-analysis
of intervention effects on satisfaction measures (O’Connor et al,
2003), some studies of breast cancer patients found positive effects of
decision aid interventions (Sawka et al, 1998; Whelan et al, 2004).
Consequently, we assessed whether the intervention influenced either
decision specific or overall patient satisfaction with treatment.
Finally, we assessed the type of treatment decision making. We
did not expect systematic differences in decision making by the
treatment arm. At each of the stages examined, patients could
choose from two treatment options, each possessing specific
advantages as well as unique problems as patients weigh benefits
and side effects of treatment choices differently. For example
women undergoing breast-conserving therapy have generally
better body image outcomes but need radiation therapy in
addition to surgery with its long-term side effects on well-being.
These women also have a higher risk of recurrence, whereas
patients who opt for mastectomy may have ‘peace of mind’ but are
more likely to experience body image disruptions and sexual
problems. Although women with early-stage breast cancer who
undergo adjuvant chemotherapy in addition to hormonal therapy
may feel more secure with regards to tumour recurrence, they are
at risk of long-term decrements in quality of life including
cognitive impairment whereas patients who decide against
chemotherapy may feel anxious not having tapped into the full
potential of oncology treatment. Women who decide on pre-
operative chemotherapy choose a treatment regimen for which no
long-term results are available at the time of trial conduction but
value breast-conserving therapy as very important whereas those
who decide on standard treatment receive a treatment that has
been better studied.
PATIENTS AND METHODS
Sample
We recruited patients with a strong suspicion of having breast
cancer from the gynaecological department of the University of
Munich-Grosshadern. A potential breast cancer diagnosis was
derived from extensive diagnostic procedures (mammogram,
ultrasound, MRI). In addition, routine breast biopsy was
conducted for patients with T2 or T3 tumour size as measured
by ultrasound. Patients were identified in an inpatient setting and
asked if they would be willing to participate in the study by two
research psychologists. Eligible patients (a) had histologically
proven breast cancer or strong suspicion through diagnostic
procedures, (b) had an operable finding (tumour sizes T1, T2, or
T3 as measured by ultrasound), (c) were between ages 18 and 75
years, (d) had no major psychiatric disease, dementia or mental
retardation, (e) had good knowledge of the German language and
(f) provided informed consent to the study. Patients were excluded
if they had (a) a previous history of breast cancer (and in situ
breast cancer) or other malignant tumours (except cured
carcinoma in situ), (b) Stage IV breast cancer, (c) a medical
contraindication for breast-conserving therapy or radiation in
patients with tumour size T1, (d) co-morbidities that resulted in a
distinct treatment option, leaving no range for choice, such as
pregnancy and lactation.
Study design
A two-arm, randomised controlled trial with decision aids vs
standard treatment was conducted. Randomisation was conducted
after the patient gave written informed consent to participate in
the trial. Blinding was not possible within the hospital procedures.
Nonetheless, in most cases physicians did not know in which arm
patients had been randomised. Patients were assessed pre-
randomisation (baseline) and at 1 week follow-up. The baseline
questionnaire was filled out shortly after hospital admission and
prior to randomisation. A few hours later, the intervention group
received a 20-min decision aid intervention and additional written
information, whereas the control group received standard care. For
completion of the follow-up, patients received a pre-paid envelope
to send back the questionnaire. The study was approved by the
ethics committee of the University of Munich.
The project used a multi-method approach and included a
qualitative study of interviews (patients, physicians, shared
decision making experts) and video analyses of doctor–patient
interactions of treatment-planning consultations within the
randomised controlled trial. A grounded theory methodology
was used to analyse these qualitative data. Results have been
published previously (Caspari, 2007) and, therefore, are not the
focus of this paper.
Procedure
We adapted the decision board introduced by Whelan et al (1999)
as a decision aid for the surgical treatment of primary breast
cancer. In addition, two new decision boards were developed: one
for the decision of additional chemotherapy in women with
hormone-responsive breast cancer (tumour size T1) and one for
patients with tumour size T2 or T3 considering preoperative
chemotherapy which was offered within the preoperative
chemotherapy clinical trial PREPARE at the time the study was
conducted. Additional details on the development of the three
decision boards, their contents, and pilot testing are described
elsewhere (Vodermaier et al, 2004).
Staff doctors informed the two research psychologists (CC, JK)
who recruited the patients about new patients who had entered the
ward and who were eligible for the trial. Randomisation was
conducted after the patient gave written informed consent to
participate in the trial through the research staff. Random
assignment was performed by means of numbered cards in
envelopes for the intervention and the control group, and was
stratified by age group (o, X60 years). For participants of the
intervention arm, the decision board intervention was provided by
research psychologists who had previously recruited the patients.
The intervention was conducted on the day the patients arrived in
the hospital after completion of the baseline questionnaire and
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subsequent surgery usually on the following day. The decision
board intervention took about 20min and contained four steps.
First, patients were explicitly informed about options on which to
decide upon and the possibility of participating in decision-
making (equipoise statement, Elwyn et al, 2000). Next, the two
treatment options were explained to the patient. In the third step
patients’ understanding of the treatment options was discussed.
Lastly, options were related to the patient’s personal situation. The
intervention aimed at motivating patients to ask questions during
the physician consultation, to participate in treatment planning, to
take time for decision making, and eventually to discuss treatment
options with family members.
Patients also received an information brochure with the content
of the decision board after the intervention, which remained with
the patient and provided them with the opportunity to review
information they had received during the intervention. Usually, a
few hours after the intervention patients had their appointment
with the senior physician with whom they planned surgery and
further appointments. In the control arm, as in standard care, the
appointment with the senior physician is the time point in hospital
procedures during which treatment decision-making usually takes
place. Hence, participants of the intervention arm received an
informational and decisional intervention and a brochure in
addition to standard care.
Patients with a strong suspicion of having early breast cancer
(tumour size T1) received decision board I concerning surgical
decision making (lumpectomy and radiation vs mastectomy).
Mastectomy decision making also contained information about the
possibility of breast reconstruction.
Within this group, women with hormone-responsive breast
cancer also received the information booklet about the decision for
or against chemotherapy in addition to hormonal therapy
containing the same information as its respective decision board.
The results of the hormone receptor did not consistently arrive
within a time frame that allowed an additional intervention as
patients had been generally discharged within 1 week of admission.
Consequently, the originally planned additional decision aid
intervention in this patient subgroup could not be performed.
Eligible patients, therefore, received the information booklet only
during their inpatient stay.
Patients with more advanced breast cancer (tumour size T2 or
T3) were presented decision board III comparing preoperative
chemotherapy followed by surgery vs standard therapy (surgery
followed by chemotherapy) in the intervention arm. The decision
aid for patients with T2 or T3 breast cancer discussed both the
question of whether or not to undergo preoperative chemotherapy
as well as the consequences of the respective treatment choice on
the cosmetic outcome. It was explained that the possibility of
breast-conserving therapy depends on the relation between
tumour size and breast size and, therefore, breast-conserving
therapy may not be possible for women with larger lumps.
The decision aid also informed about the possibility of
breast reconstruction for these women. Moreover, the decision
aid shortly stated the issue of leaving the lump for a few
additional months in the breast and that in consequence for some
women immediate surgery might be psychologically more
beneficial.
Measures
Patients were assessed with the following instrumentation:
Primary outcome variable
Decisional conflict. The Decisional Conflict Scale (DCS; O’Connor,
1995) measures patients’ uncertainty about which treatment to
choose, factors contributing to uncertainty (believing to be
uninformed, unclear values, and unsupported in decision making),
and perceived effectiveness of decision making. Questions have to
be answered on a 5-point Likert scale. Higher scores on the scale or
subscales reflect higher decisional conflict, uncertainty, and a less
effective choice. The German version of the scale demonstrated
subscale and total score internal consistencies in the present
sample between 0.73 and 0.94. The scale discriminates between
patients who make and those who delay decisions (O’Connor,
1995; Bunn and O’Connor, 1996) and is sensitive to change
(O’Connor et al, 1998).
Secondary outcome variables
Uptake rates of treatment options. For participants with
supposed early-stage breast cancer (tumour size T1), we
assessed the type of surgery (breast-conserving therapy and
radiation vs mastectomy) and whether additional chemotherapy
was chosen in patients with hormone-responsive tumours. Patients
with tumour size T2 or T3 were monitored as to whether they
opted for preoperative chemotherapy or standard treatment.
Information on the patients’ treatment was taken from the
patients’ charts.
Length of consultation. Patients were asked about the amount of
time the physician spent with them for treatment planning, with
the following categories: 5–10, 10–15, 15–25, 25–35, more than
35min.
Time point of decision making. Patients were asked to indicate at
what time the treatment decision making took place. The potential
options provided were: during treatment-planning session, the
same day, the day after, or several days later.
Patient perception of treatment decision making. Patients were
asked on a five-point scale to what degree the doctor or the
patient decided about the treatment with the following
categories: physician decided alone, physician decided predomi-
nantly, treatment decision making was equally shared between
doctor and patient, patient decided predominantly, patient decided
alone.
Perceived involvement in care. To examine whether the decision
aid intervention influenced physician–patient interaction, we
applied the German version of the Perceived Involvement in Care
Scale (PICS; Lerman et al, 1990; Scheibler et al, 2004). The PICS
consists of three subscales: doctor facilitation of patient involve-
ment, level of information exchange, and patient participation in
decision making. At the time of patient recruitment only two
subscales of the German version (doctor facilitation, patient
information) had adequate psychometric properties (Scheibler
et al, 2004) and were included in the study. The answering format
is a 4-point Likert scale with higher scores reflecting more
involvement. The split half reliability coefficients (Spearman–
Brown) of the two subscales were 0.84 and 0.79, respectively
(Scheibler et al, 2004).
Satisfaction. To measure satisfaction related to various aspects of
the decision making process we used a scale developed by
Man-Son-Hing et al (1999). The scale consists of six items
(Table 1), which were analysed individually in the original report.
Questions have to be answered on a 5-point scale.
To assess general patient satisfaction, the German Version of the
Client Satisfaction Scale, the ZUF8 (Attkisson and Zwick, 1982;
Schmidt et al, 1989) was included. The scale consists of eight items
with being answered on a 4-point Likert scale. The scale’s
reliabilities in different samples were between 0.87 and 0.93 and
correlated with treatment outcomes (Schmidt et al, 1989).
Demographic and clinical variables
Demographic variables. Data were collected on the women’s age,
marital status, education level, and employment status.
Clinical variables. We assessed tumour size, nodal status, grading,
and hormone receptor status.
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sStatistical considerations
To detect a medium effect size (r¼0.3) with a power of 0.80
and a type I error of 0.05 at least 85 patients had to be enrolled
in the study (Cohen, 1977). Group comparisons were calculated
with independent sample t-tests for continuous variables and
w
2-test and Fisher’s exact test for categorical variables.
The outcome categories of the treatment-specific satisfaction
scale (Man-Son-Hing et al, 1999) were reduced to two, based
on clinical importance (satisfied vs undecided or unsatisfied) and
also to make sure that there were enough patients in each
response category for the analyses. Likewise, the patient rating on
the degree of participation in treatment decision making was
reduced to three categories: primarily the physician decided,
shared decision, and primarily the patient decided. All P-values
reflect two-tailed tests.
RESULTS
Trial retention
Between May 2003 and October 2004 we invited 246 patients to
participate, of whom 94 declined (uptake rate of 62.6%). Patient
accrual according to the Consort guidelines is presented in
Figure 1. The major reasons for declining study participation
were preoperative distress associated with filling out a question-
naire shortly after admission (70%), general refusal to fill out
questionnaires (10%), involvement in another study therefore not
wanting to participate in an additional study (2%), first agreed to
participate, but refused after reviewing the questionnaire (4%) or
were ineligible because of missing diagnostic findings, outstand-
ing examinations, or preoperative chemotherapy before having
filled out the baseline questionnaire (4%). 152 participants were
randomised to either the intervention or the control condition.
The final sample was 111 patients, of whom 55 were
randomly assigned to the intervention group and 56 to the control
group. Here, 13 and 16 patients respectively were excluded from
the analyses because of post hoc ascertainment of not having met
the inclusion criteria (benign diagnosis, carcinoma in situ, Stage
IV-tumour).
Sample characteristics and success of randomisation
No group differences in terms of demographic and tumour-related
variables were found (Table 2). Participants’ mean age was 53.5
and 56.9 years, respectively. Seventy-three percent of the sample
was married or common law. One third of participants had at least
a high school degree and 20% reported graduating from university.
About half of the sample was in part or fulltime employment at the
time of their diagnosis.
Fifty-nine percent of participants had T1 breast cancer. The
remaining had T2 and T3 breast tumours. Eighty-one percent had
node-negative breast cancer. As no routine preoperative breast
biopsy was offered for early-stage breast cancer patients during
the conduct of the study, results from tumour biologic analyses
differed somewhat from the pre-randomisation assessment
(Table 2).
Primary outcome variable
Decisional conflict. Overall, participants experienced a modest
amount of decisional conflict. No intervention effect emerged on
the decisional conflict total scale. Among subscales, a significant
group effect, effect size Zp
2 ¼0.06, on the ‘uninformed’ subscale
revealed that patients of the intervention group felt more informed
as compared to the control group (Table 3).
Secondary outcome variables
Perceived involvement in care. No group differences were found in
patients’ perception of the extent of involvement in the treatment
choice (Table 3). Here, 67% of participants reported that they
shared the decision-making with their physician, 28% that the
physician was more influential on the decision, and 6% found that
they themselves were more influential.
Patients reported a moderate to high amount of patient
activation by the doctor and their information seeking behaviour,
which did not vary as a function of the treatment arm (Table 3).
Length of consultation. No time differences emerged in the length
of the treatment decision consultation with the physician on
patient self-reports. The mean time for the treatment decision
making appointment was about 15min. (Table 4)
Time point of decision making. In all 75% of participants reported
that the decision was made during the treatment-planning session.
Only 12% of patients reported having spent a day or more to
decide on a specific option. Groups did not differ in the time frame
used for treatment decision making.
Satisfaction with decision and treatment. Overall, participants
reported high satisfaction with the decision making process and
general satisfaction with treatment, which did not vary as a
function of the treatment arm.
Subgroup analyses
Uptake rates of treatment options. In subgroup analyses we tested
whether treatment decisions varied as a function of study arm. The
decision aid intervention did not influence uptake rates of any of
the three treatment options (Table 4). Most patients with T1 breast
cancer (91%) opted for breast-conserving therapy. Also, no group
differences emerged in uptake rates of chemotherapy in the
subgroup of patients with hormone-responsive early breast cancer
and decision making towards preoperative chemotherapy in
women with more advanced breast cancer. Thirty percent of
participants with T1 breast cancer disease decided for chemother-
apy in addition to hormone therapy whereas 55% (IG: 62.3% vs
Table 1 Impact on satisfaction with decision and treatment
Variable
(range)
Intervention
group
Control
group
v
2/Fisher’s
test P-value
Physician helped me to understand results
Yes 49 (92.5%) 53 (94.6%) 0.22 0.71
No 4 (7.5%) 3 (5.4%)
Physician understood what is important to me
Yes 47 (88.7%) 50 (90.9%) 0.15 0.70
No 6 (11.3%) 5 (9.1%)
Physician answered all questions
Yes 47 (88.7%) 51 (92.7%) 0.53 0.52
No 6 (11.3%) 4 (7.3%)
Satisfied with involvement in decision making
Yes 44 (83.0%) 45 (83.3%) o0.01 0.97
No 9 (17.0%) 9 (16.7%)
Satisfied with physician’s involvement
Yes 36 (75.0%) 36 (76.6%) 0.03 0.86
No 12 (25.0%) 11 (23.4%)
Satisfied with process
Yes 42 (89.4%) 50 (92.6%) 0.32 0.73
No 5 (10.6%) 4 (7.4%)
ZUF-8 (4–32) 29.08 (2.99) 28.67 (2.86) 0.71 0.48
Decision aids and breast cancer treatment
A Vodermaier et al
593
British Journal of Cancer (2009) 100(4), 590–597 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sCG: 46.7%) of patients with more advanced disease decided for
preoperative chemotherapy.
DISCUSSION
Overall, the decision aid intervention in patients with newly
diagnosed breast cancer had little impact on the patients’
experience of the treatment decision making procedure. The main
hypothesis, that participants of the intervention arm were less
likely to experience decisional conflict cannot be confirmed.
However, on the ‘information’ subscale of the decisional conflict
scale which is considered as one of two indicators of decision
quality (O’Connor et al, 2003), patients who underwent the
decision aid intervention reported feeling better informed
than participants in the control arm. Effects on informational
levels have been also shown in other studies in women with
newly diagnosed breast cancer (Sawka et al, 1998; Whelan et al,
2003, 2004).
No other differences emerged between groups. In line with other
studies (Sepucha et al, 2000; Whelan et al, 2003), no effect was
found on the length of the consultation with the senior physician
being the main doctor with whom to decide upon the following
treatment. Thus, existing data do not support the notion that
decision support interventions affect physicians’ timing but the
doctors’ consultation may vary by themes from basic knowledge
translation to more individual patient counselling. In this study,
however, unblinding of conditions may have resulted in some
reactivity of physicians with taking more emphasis on counselling
patients in terms of shared decision making in the control group.
Nonetheless, a minority of physicians may have been aware of the
patients’ group status of the trial.
No group differences emerged in patients’ self-report of doctors’
behaviour. Patients reported the same amount of involvement in
without prior intervention as randomised (n=78) 
Elgible to enter trial (n=246)
Refused participation (n=94)
Random assignment (n=52)
Allocated to intervention group (n=74) 
Completed baseline questionnaire assessment 
and received intervention before consultation with 
the physician as randomised (n=74) 
Allocated to control group (n=78)
Completed baseline questionnaire assessment 
and received consultation with the physician 
Lost to follow-up (n=6)  Lost to follow-up (n=6) 
Data analysed (n=55) 
Excluded from data analysis  
(Reasons: benign finding, n=8, DCIS, n=2,
T4-tumour, n=3) 
Data analysed (n=56) 
Excluded from data analysis 
(Reasons: benign finding, n=11, DCIS, n=5) 
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Figure 1 Trial accrual and retention.
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scare and the same proportion of decision autonomy independent
of group membership. Two explanations may be responsible for
these results. Independent of the intervention arm, most
participants experienced a high degree of participation in
treatment decision making. Consequently, treatment decision
making counselling may have had, a-priori, met shared decision
making criteria. On the other hand, the procedures of inpatient
counselling, for the majority of patients one day prior to surgery,
seem to be inadequate to implement a shared decision making
approach. Because shared decision making may have implicitly,
become a standard in patient counselling, possibly also activated
through the conduct of the trial, an additional effect of the
intervention may have been prevented by the inpatient treatment
setting. In line with these results, the time point of decision making
did not vary as a function of treatment arm as well.
A different interpretation of the data can be derived from the
qualitative analysis of video-taped treatment consultation planning
sessions with the senior physician during the conduct of the trial
(Caspari, 2007). These findings suggest that most patients desire a
quick treatment, trust their physicians in the uncertain situation,
and do not discriminate between shared decision making and the
relationship to their physician. A high level of trust in the
physician is experienced as equivalent to participating in treatment
decision making. Hence, derived from qualitative data of the trial,
patient involvement in treatment decision making does not
contradict decision delegation to the physician. It could have
been possible that the doctor–patient interaction coloured the
evaluation of the treatment decision and may explain lacking
group differences of the randomised controlled trial.
Furthermore, no group differences in treatment choice emerged.
However, uptake rates of breast-conserving therapy significantly
exceeded rates reported in other studies, especially in the control
condition (Street et al, 1995; Molenaar et al, 2004; Whelan et al,
2004). Therefore, a ceiling effect may have emerged on this
variable. Other evidence demonstrated that the endorsement of
breast loss and fear of recurrence predicted either uptake of
lumpectomy or mastectomy and not the introduction of decision
aids (Molenaar et al, 2004). With regards to chemotherapy, about
Table 2 Descriptive statistics [M(s.d.) and n(%)] for demographic and
tumor-related variables
Variable
Intervention
group
Control
group
t/v
2/Fisher’s
test P-value
Age (n¼111) 53.53 (11.67) 56.86 (10.10)  1.61 0.11
Married/cohabiting (n¼111)
Yes 40 (72.7%) 41 (73.2%) 0.003 0.95
No 15 (27.3%) 15 (26.8%)
High school (n¼111)
Yes 18 (67.3%) 17(69.6%) 0.07 0.79
No 37 (32.7%) 39 (30.4%)
University degree (n¼107)
Yes 13 (24.5%) 9 (16.7%) 1.01 0.31
No 40 (75.5%) 45 (83.3%)
Employed (n¼110)
Yes 27 (50.0%) 25 (44.6%) 0.32 0.57
No 27 (50.0%) 31 (55.4%)
Tumour size (n¼104)
a
T1 30 (58.8%) 31 (58.5%) 0.26 1.00
T2 19 (37.3%) 19 (35.8%)
T3 2 (3.9%) 3 (5.7%)
N0 (n¼104)
Yes 45 (88.2%) 40 (75.5%) 2.84 0.09
No 6 (11.8%) 13 (24.5%)
Hormone receptor (n¼110)
b
Positive 48 (88.7%) 49 (90.4%) 0.09 0.78
Negative 7 (11.3%) 6 (9.6%)
Grading 3 (n¼108)
Yes 13 (24.1%) 14 (25.9%) 0.05 0.82
No 41 (75.9%) 40 (74.1%)
aActual tumour size was different from pre-randomisation assessment which resulted
in a higher proportion of patients clinically classified with T1 breast cancer than after
tumour biologic analyses.
bNumbers are different from Table 4 (limitation to T1
breast cancer) whereas here information on the hormone receptor status is given for
the whole sample.
Table 3 Impact on decisional conflict
Variable
(range)
Intervention
group
Control
group t-test P-value
DCS uncertainty (1–5) 2.08 (0.97) 2.20 (0.90)  0.65 0.52
DCS uninformed 1.88 (0.63) 2.17 (0.79)  2.01 0.048
DCS unclear values 1.83 (0.62) 1.99 (0.79)  1.16 0.25
DCS unsupported 1.65 (0.65) 1.84 (0.63)  1.49 0.14
DCS ineffective choice 2.13 (0.83) 2.40 (0.80)  1.68 0.10
DCS total 1.82 (0.59) 1.99 (0.62)  1.36 0.18
PICS doctor facilitation (1–4) 2.65 (0.66) 2.72 (0.67)  0.56 0.58
PICS patient information 3.04 (0.74) 3.09 (0.73)  0.35 0.73
Table 4 Impact on treatment decision making
Variable
Intervention
group
Control
group
t/v
2/Fisher’s
test P-value
Breast-conserving therapy (n¼80)
a
Yes 37 (94.9%) 36 (87.8%) 2.01 0.27
No 2 (5.1%) 5 (12.2%)
Chemotherapy (n¼74)
a
Yes 11 (31.4%) 11 (28.2%) 0.09 0.80
No 24 (68.6%) 28 (71.8%)
Pre-operative chemotherapy (n¼31)
a
Yes 10 (62.5%) 7 (46.7%) 0.78 0.48
No 6 (37.5%) 8 (53.3%)
Length of consultation (n¼107)
5–10min 6 (11.3%) 5 (9.3%) 1.03 0.91
10–15min 17 (32.1%) 19 (35.2%)
15–25min 15 (28.3%) 14 (25.9%)
25–35min 7 (13.2%) 5 (9.3%)
Above 35min 8 (15.1%) 11 (20.4%)
Decision making (n¼97)
During
treatment
planning session
36 (75.0%) 38 (77.6%) 0.64 0.93
The same day 6 (12.5%) 5 (10.2%)
The day after 2 (4.2%) 3 (6.1%)
Several days later 4 (8.3%) 3 (6.1%)
Patients’ perception of decision making (n¼107)
Primarily the
physician
14 (26.4%) 16 (29.6%) 0.81 0.72
Shared 35 (66.0%) 36 (66.7%)
Primarily the
patient
4 (7.5%) 2 (3.7%)
aDifferent subsamples were tested. Percentages reflect decisions within decisional
options patients’ were provided and are somewhat different from tumour biological
results, which were provided later.
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treatment. Although one study reported no effect on adjuvant
treatment decision making either (Whelan et al, 2003), a decrease
in adjuvant chemotherapy uptake in the group of patients who
received a decision aid has been reported (Peele et al, 2005;
Siminoff et al, 2006). Owing to the size of the subsample results on
uptake rates of preoperative chemotherapy decision making have
to be considered as preliminary. It would be interesting if this
trend found in subgroup analyses could be replicated in a larger
study with more power to detect a significant effect. As outlined
earlier, however, differences in treatment choice should not be
considered as an indicator of informed decision making or
decision aid efficacy.
Satisfaction with the decision making process and general
patient satisfaction with care was high and did not differ between
groups. Though physicians involved in the patients’ treatment did
not see patients’ assessment of treatment satisfaction, ratings were
not blind to the research psychologists who performed the
intervention. This may have lead to social desirability with regard
to the evaluation of the decision aid intervention but may have had
little impact on ratings of satisfaction with treatment. Variance
constriction because of a ceiling effect may have contributed to the
lack of a group difference. Results are in line with other studies,
which reported null effects of decision aids on satisfaction
judgements (Sawka et al, 1998; Whelan et al, 1999), whereas some
studies demonstrated short (Whelan et al, 2004) or long-term
effects (Molenaar et al, 2001). Discrepant findings may be related
to individual differences in cognitive processing of the decision
making phase on which the decision aids also have an impact. For
most women with breast cancer the treatment-planning phase is a
highly remembered time point in the disease trajectory. Many
women feel relief post-treatment, experience few decisional
conflict and satisfaction with treatment. On the other hand, some
patients experience ongoing doubts and uncertainty whether they
have undergone the ‘right’ treatment or even experience feelings of
regret for not having taken some aspects into consideration they
value important in retrospect (Lantz et al, 2005; Sheehan et al,
2007). The degree to which patients experience high uncertainty or
regret could both depend on situation-specific experiences how
their treatment decision making occurred as well as on a rather
stable personality trait of frequent rumination. These patient
characteristics may interact with decision aid interventions on
outcome measures.
The study’s findings must be considered in relation to some
limitations. A notable proportion of patients invited to participate
in the study declined and a considerable number of post-
randomisation exclusions occurred due to the fact that an invasive
breast cancer diagnosis was not confirmed prior to randomisation
by means of a lack of preoperative breast biopsy. As we wanted to
assess the effect of the intervention in breast cancer patients, we
decided to only include participants with invasive breast cancer
and excluded patients with benign disease, ductal carcinoma in
situ, and metastatic diseases from the analyses. Patients with
benign findings experience a huge relief, which may colour the
evaluation of the decision aid intervention whereas patients with
DCIS have less treatment options and patients with metastatic
disease are facing completely different decisions and challenges.
Furthermore, the results of the study are limited to one centre
and the study was not powered to detect effects on treatment
decision making in subgroup analyses, especially with regards to
detecting intervention effects on the decision towards preoperative
chemotherapy. Also, randomisation performed by a computer is a
more robust method than the random assignment by research staff
as conducted in this study.
Except for treatment decision making, all outcome variables
were based on self-report measures. Specifically, patients’ reports
on the length of the consultation with the senior physician in
which the decision was discussed or even finalised may have
involved some inaccuracy of measurement. However, it was not
possible within the study to obtain independent time assessments.
A strength of the current study is its representativeness. The
sample did not differ in terms of demographic and tumour-related
characteristics from the regional epidemiological tumour registry
database of breast cancer patients for southern Bavaria (Engel
et al, 2005), suggesting the study’s generalisability with regards to
the study sample. In terms of the treatment setting the findings are
generalisable to university hospital treatment for breast cancer.
The introduction of decision aids in general hospitals may likely
differ with regards to lower standards of patient counselling and
consequently may heighten the importance of decision aids for
information provision.
In conclusion, this study showed a small effect of a decision aid
intervention in newly diagnosed breast cancer patients in the
hospital inpatient setting on their subjective level of information.
These almost null findings may be related to a pre-existing high
standard of shared decision making realisation in the physicians’
guidance of patients or circumstances in the inpatient treatment
setting that hinder achieving further improvements through the
introduction of decision aids. Hence, the study suggests that
contextual factors (i.e., inpatient treatment, short time frame for
decision making) may explain low decision aid effectiveness.
As decision aid interventions in the treatment of cancer patients
have demonstrated rather small effects across diseases, future
research may address the role of contextual factors that promote
the implementation and effectiveness of shared treatment decision
making. Moreover, the shared decision making paradigm suggests
that shared medical decision making involves favourable effects for
all patients. No randomised controlled trial to date examined the
role of patients’ decisional preferences on decision aid effective-
ness. Hence, offering decision aid interventions to subgroups of
patients who state a strong preference for shared decision making
may result in larger effect sizes for these kinds of tools. The
examination of individual differences, therefore, may identify
subgroups of patients who may derive more benefits from the
introduction of decision aids than their application across all
patients.
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